PTC Therapeutics (PTCT) Buy Rating Maintained at Deutsche Bank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
PTC Therapeutics (PTCT) Pares Move Higher Following M&A Speculation (BMRN)
February 23, 2015 12:28 PM ESTPTC Therapeutics (NASDAQ: PTCT) is paring some gains related to M&A speculation. One noted biotech watcher thinks a move for BioMarin (Nasdaq: BMRN) to acquire PTCT is unlikely.
$BMRN is interested in buying $PTCT? Thats hard to believe.
— Adam Feuerstein (@adamfeuerstein) February 23, 2015... More
UPDATE: PTC Therapeutics (PTCT) pops; said to be exploring possible sale - Reuters
February 23, 2015 12:03 PM EST(Updated - February 23, 2015 12:43 PM EST)
PTC Therapeutics (NASDAQ: PTCT) pops on chatter the company is exploring a sale, according to Reuters headlines.
According to the report, the company has received takeover interest from several pharmaceutical companies including Shire plc (NASDAQ:... More



